Alnylam Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US02043Q1076

SecurityALNY / Alnylam Pharmaceuticals, Inc.
InstitutionGhost Tree Capital, LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Ghost Tree Capital, LLC ownership in ALNY / Alnylam Pharmaceuticals, Inc.

On November 14, 2024 - Ghost Tree Capital, LLC filed a 13F-HR form disclosing ownership of 0 shares of Alnylam Pharmaceuticals, Inc. (US:ALNY) valued at $0 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 22,500 shares of Alnylam Pharmaceuticals, Inc.. The current value of the position is $0 USD.

Ghost Tree Capital, LLC has a history of taking positions in derivatives of the underlying security (ALNY) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ALNY / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -100.00 0
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,500 -37,500 -62.50 5,468 -39.03 1.7121
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,000 32,500 118.18 8,967 70.38 2.4819
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,500 27,500 5,264 1.7210
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,900 -100.00 0 -100.00
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,900 1,900 277 0.1443
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -30,000 -100.00 0 -100.00
2022-02-16 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,000 30,000 5,087 1.8230
2020-04-09 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -150,000 -100.00 0 -100.00
2020-04-09 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 150,000 0 0.00 10,884 -22.36 2.2575
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 150,000 0 10,884 2,279,438.5595
2020-04-09 2019-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 150,000 115,000 328.57 14,018 449.29 3.6623
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 150,000 115,000 14,018 3,797,855.8830
2020-04-09 2018-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 35,000 -140,000 -80.00 2,552 -83.34 0.9262
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,000 -140,000 2,552 895,168.4755
2020-04-09 2018-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 175,000 -35,000 -16.67 15,316 -25.95 3.2555
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 175,000 -35,000 15,316 3,262,582.9705
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 210,000 210,000 20,683 6.0870
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -35,000 -100.00 0 -100.00
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,000 -10,000 -22.22 4,112 -2.93 0.8732
2016-02-17 2015-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 45,000 45,000 0.00 4,236 1.7344
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,000 4,236
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -90,000 -100.00 0 -100.00
2015-09-09 2015-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 90,000 50,000 125.00 10,788 158.27 3.4957
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 90,000 10,788
2015-05-15 2015-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 40,000 -15,000 -27.27 4,177 -21.71 1.5020
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,000 4,177
2015-02-18 2014-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 55,000 20,000 57.14 5,335 95.14 2.5599
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,000 5,335
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,000 -40,000 -53.33 2,734 -42.30 1.4840
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 75,000 75,000 4,738 3.3418
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-04-09 2018-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-04-09 2018-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 50,000 4,376 n/a n/a n/a
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 50,000 5,250 n/a n/a n/a
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 75,000 6,027 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 68,400 16,621 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.